Case report: Nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide.
Front Endocrinol (Lausanne) · 2024
Last updated 2026-05-28Two children with a genetic cause of obesity (a mutation in the MC4R gene) were treated with semaglutide once a week for 6 months. While their weight and blood sugar control (HbA1c) showed little change, tests revealed improvements in nerve fiber regeneration, with increases in corneal nerve fiber density (13.9% and 14.7%), corneal nerve branch density (110.2% and 58.7%), and corneal nerve fiber length (21.5% and 44.0%).
AI summary of the abstract below.
| Journal | Front Endocrinol (Lausanne), 2024 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 1.73 |
| NIH percentile | 69 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
Melanocortin 4 receptor () mutations are the commonest cause of monogenic obesity through dysregulation of neuronal pathways in the hypothalamus and prefrontal cortex that regulate hunger and satiety. also regulates neuropathic pain pathways via JNK signaling after nerve injury. We show evidence of corneal small fiber degeneration in 2 siblings carrying a heterozygous missense variant c.508A>G, p.Ille170Val in the gene. Both children were treated with once weekly semaglutide for 6 months with no change in weight, and only a minor improvement in HbA1c and lipid profile. However, there was evidence of nerve regeneration with an increase in corneal nerve fiber density (CNFD) [child A (13.9%), child B (14.7%)], corneal nerve branch density (CNBD) [child A (110.2%), child B (58.7%)] and corneal nerve fiber length (CNFL) [child A (21.5%), child B (44.0%)].
Verbatim abstract via PubMed 38974580 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.